New treatment for KS offers options for therapy.
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D017277:Drug Approval; D004337:Drug Carriers; D006207:Half-Life; D006801:Humans; D008081:Liposomes; D012514:Sarcoma, Kaposi / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology / Q000821:virology; D014481:United States; D014486:United States Food and Drug Administration; D014750:Vincristine / Q000008:administration & dosage
D004337:Drug Carriers; D008081:Liposomes; D001761:Bleomycin; D014750:Vincristine; D004317:Doxorubicin